Key Takeaway: Biogen to Webcast Prerecorded Encore Aducanumab Presentation from 61st Annual Meeting of the Japanese Society of Neurology on August 31, 2020
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis
Full Press Release Details
Biogen to Webcast Prerecorded Encore Aducanumab Presentation from 61st Annual Meeting of the Japanese Society of Neurology on August 31, 2020.